Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas O Schaffland

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Nuclear Medicine Communications|April 22, 2004
The preparation of clinical grade 5-[123I]iodo-2'-deoxyuridine and 5-[125I]iodo-2'-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphyAndreas O Schaffland, Angelika Bischof Delaloye, Marek Kosinski, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 2, 2006
Short fluorodeoxyuridine exposure of different human glioblastoma lines induces high-level accumulation of S-phase cells that avidly incorporate 125I-iododeoxyuridineFlorence Perillo-Adamer, Angelika Bischof Delaloye, Céline S Genton, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
131I-rituximab: relationship between immunoreactivity and specific activityAndreas O Schaffland, Franz Buchegger, Marek Kosinski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 8, 2003
Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patientsFranz Buchegger, Florent Bonvin, Marek Kosinski, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 13, 2005
Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kineticsCristian Antonescu, Angelika Bischof Delaloye, Marek Kosinski, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Nuclear Medicine Communications|April 22, 2004
The preparation of clinical grade 5-[123I]iodo-2'-deoxyuridine and 5-[125I]iodo-2'-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphyAndreas O Schaffland, Angelika Bischof Delaloye, Marek Kosinski, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 2, 2006
Short fluorodeoxyuridine exposure of different human glioblastoma lines induces high-level accumulation of S-phase cells that avidly incorporate 125I-iododeoxyuridineFlorence Perillo-Adamer, Angelika Bischof Delaloye, Céline S Genton, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
131I-rituximab: relationship between immunoreactivity and specific activityAndreas O Schaffland, Franz Buchegger, Marek Kosinski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 8, 2003
Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patientsFranz Buchegger, Florent Bonvin, Marek Kosinski, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 13, 2005
Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kineticsCristian Antonescu, Angelika Bischof Delaloye, Marek Kosinski, et al.
Pageof 1